Last week, Spotlight-listed Cereno Scientific got the acceptance from the FDA regarding their IND application for initiating a phase II trial with CS1 in the rare disease pulmonary arterial hypertension. CEO Sten R Sörensen visited BioStock’s studio and told us more about what this milestone means for Cereno Scientific.
Watch the interview in Swedish with Cereno Scientific’s CEO Sten R Sörensen in the link below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.